Pitting phosphate transport inhibitors against vascular calcification

Circulation Research

Volumn 98, Issue 7, 2006, Pages 857-859

  Demer, Linda L ^a,b   Tintut, Yin ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Calcification; Mineralization; Phosphate transport; Pit 1; Vascular

Indexed keywords

ALKALINE PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE; BONE MORPHOGENETIC PROTEIN 2; CALCITRIOL; CATENIN; CYTOKINE; DECORIN; ESTRADIOL; FETUIN; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LEPTIN; MATRIX PROTEIN; NICOTINE; OSTEOCALCIN; OSTEOPONTIN; OSTEOPROTEGERIN; PARATHYROID HORMONE; PARATHYROID HORMONE RELATED PROTEIN; PHOSPHATE TRANSPORT INHIBITOR; PHOSPHATE TRANSPORTER; PROTEIN TYROSINE KINASE; PYROPHOSPHATE; SOMATOMEDIN C; TRANSCRIPTION FACTOR MSX2; TRANSCRIPTION FACTOR PIT 1; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN; WNT1 PROTEIN; CELL RECEPTOR; GLYCOPROTEIN; SODIUM PHOSPHATE COTRANSPORTER; TNFRSF11B PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RECEPTOR;

BLOOD VESSEL CALCIFICATION; CELL DIFFERENTIATION; CYTOARCHITECTURE; EDITORIAL; HEMODIALYSIS PATIENT; HUMAN; HYPERPHOSPHATEMIA; PHOSPHATE TRANSPORT; PRIORITY JOURNAL; ANIMAL; CALCINOSIS; CORONARY ARTERY DISEASE; DRUG ANTAGONISM; GENETICS; NOTE; PHYSIOLOGY; VASCULAR SMOOTH MUSCLE;

ANIMALS; CALCINOSIS; CORONARY DISEASE; GLYCOPROTEINS; HUMANS; MUSCLE, SMOOTH, VASCULAR; OSTEOPROTEGERIN; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; SODIUM-PHOSPHATE COTRANSPORTER PROTEINS;

EID: 33646145732     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.0000219673.71778.df     Document Type: Editorial

References (20)

1. Goodman WG. Vascular calcification in chronic renal failure. Lancet. 2001;358:1115-1116.
2. Jono S, McKee MD, Murry CE, Shioi A, Nishizawa Y, Mori K, Morii H, Giachelli CM. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res. 2000;87:E10-E17.
3. Li X, Yang H-Y, Giachelli CM. Role of the sodium dependent phosphate cotransporter, Pit-1, in vascular smooth muscle cell calcification. Circ Res. 2006;98:905-912.
4. Abedin M, Tintut Y, Demer LL. Vascular calcification: mechanisms and clinical ramifications. Arterioscler Thromb Vasc Biol. 2004;24:1161-1170.
5. Collett GD, Canfield AE. Angiogenesis and pericytes in the initiation of ectopic calcification. Cirr Res. 2005;96:930-938.
6. Giachelli CM. Vascular calcification mechanisms. J Am Soc Nephrol. 2004;15:2959-2964.
7. Shao JS, Cheng SL, Charlton-Kachigian N, Loewy AP, Towler DA. Teriparatide (human parathyroid hormone (1-34)) inhibits osteogenic vascular calcification in diabetic low density lipoprotein receptor-deficient mice. J Biol Chem. 2003;278:50195-50202.
8. Luo G, Ducy P, McKee MD, Pinero GJ, Loyer E, Behringer RR, Karsenty G. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature. 1997;386:78-81.
9. Kaden JJ, Bickelhaupt S, Grobholz R, Haase KK, Sarikoc A, Kilic R, Brueckmann M, Lang S, Zahn I, Vahl C, Hagl S, Dempfle CE, Borggrefe M. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulate aortic valve calcification. J Mol Cell Cardiol. 2004;36:57-66.
10. Johnson K, Polewski M, van Etten D, Terkeltaub R. Chondrogenesis mediated by PPi depletion promotes spontaneous aortic calcification in NPP1-/- mice. Arterioscler Thromb Vasc Biol. 2005;25:686-691.
11. Rutsch F, Vaingankar S, Johnson K, Goldfine I, Maddux B, Schauerte P, Kalhoff H, Sano K, Boisvert WA, Superti-Furga A, Terkeltaub R. PC-1 nucleoside triphosphate pyrophosphohydrolase deficiency in idiopathic infantile arterial calcification. Am J Pathol. 2001;158:543-554.
12. Gaur T, Lengner CJ, Hovhannisyan H, Bhat RA, Bodine PV, Komm BS, Javed A, van Wijnen AJ, Stein JL, Stein GS, Lian JB. Canonical WNT signaling promotes osteogenesis by directly stimulating Runx2 gene expression. J Biol Chem. 2005;280:33132-33140.
13. Shao JS, Cheng SL, Pingsterhaus JM, Charlton-Kachigian N, Loewy AP, Towler DA. Msx2 promotes cardiovascular calcification by activating paracrine Wnt signals. J Clin Invest. 2005;115:1210-1220.
14. Shea CM, Edgar CM, Einhorn TA, Gerstenfeld LC. BMP treatment of C3H10T1/2 mesenchymal stem cells induces both chondrogenesis and osteogenesis. J Cell Biochem. 2003;90:1112-1127.
15. Schoppet M, Al-Fakhri N, Franke FE, Katz N, Barth PJ, Maisch B, Preissner KT, Hofbauer LC. Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor-kappaB ligand in Monckeberg's sclerosis and atherosclerosis. J Clin Endocrinol Metab. 2004;89:4104-4112.
16. Shanahan CM, Cary NR, Metcalfe JC, Weissberg PL. High expression of genes for calcification-regulating proteins in human atherosclerotic plaques. J Clin Invest. 1994;93:2393-2402.
17. Price PA, June HH, Buckley JR, Williamson MK. Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arterioscler Thromb Vasc Biol. 2001;21:1610-1616.
18. Henley C, Colloton M, Cattley RC, Shatzen E, Towler DA, Lacey D, Martin D. 1,25-Dihydroxyvitamin D3 but not cinacalcet HCl (Sensipar/Mimpara) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism. Nephrol Dial Transplant. 2005;20:1370-1377.
19. Schurgers LJ, Aebert H, Vermeer C, Bultmann B, Janzen J. Oral anticoagulant treatment: friend or foe in cardiovascular disease? Blood. 2004;104:3231-3232.
20. Cheng SL, Shao JS, Charlton-Kachigian N, Loewy AP, Towler DA. MSX2 promotes osteogenesis and suppresses adipogenic differentiation of multipotent mesenchymal progenitors. J Biol Chem. 2003;278:45969-45977.